Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience

Abstract

Background: Gastrointestinal and extraintestinal malignancies are long-term complications in patients with inflammatory bowel disease (IBD), likely as a result of chronic inflammation and the use of immunosuppressive medications used to control inflammation. Here, we assessed the frequency of malignancies in a large tertiary IBD centre at the University Hospital Zurich. Methods: We performed a retrospective analysis of data from 1,026 patients from our IBD clinic treated between 2007 and 2014. Results: Twenty two of the 1,026 patients developed 28 cases of malignancies, 14 patients were male and 8 patients female. The median latency between IBD diagnosis and first malignancy was 13 years (range 2-27 years). Most common malignancies were non-Hodgkin lymphoma, colorectal cancer (CRC), urothelial carcinoma, cholangiocellular carcinoma (CCC) and prostate cancer. The most common tumour type in Crohn's disease patients (13/22) was lymphoma (5 cases), in ulcerative colitis patients (9/22) CCC (2 cases) and CRC (2 cases). The observed incidence of lymphoma (32.5/100,000), bladder carcinoma (21.7/100,000) and CCC (10.8/100,000) was higher than expected and known from general population. All of the patients that developed a malignancy had received immunosuppressive therapy. Compared to a cohort of 927 IBD patients without malignancies there were no statistical differences regarding gender, antibodies targeting tumour necrosis factor and thiopurine use. Conclusion: Our data support the assumption that a long-standing disease course and immunosuppressive therapy increase the risk for developing malignancies in IBD patients.

Risk of Urinary Bladder Cancer in Patients With Inflammatory Bowel Diseases: A Meta-Analysis

“…More importantly, patients with CD and UC are at increased risk of both intestinal and extraintestinal malignancies, and they have a higher risk of developing invasive cancer than the general population, including lymphoma, melanoma, and cholangiocarcinoma ( 7 ). However, there is a lack of conclusive evidence demonstrating the risk of urinary bladder cancer (BC), the ninth most common cancer around the world, in IBD patients ( 8 , 9 ). Here, we carried out a comprehensive meta-analysis to investigate the relationship between IBD and the risk of BC.…”

Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission

“…Moreover, it has been reported that patients who achieve mucosal healing have lower rates of hospitalization and a lower risk of colectomy [1, 2]. Furthermore, in UC patients, a prolonged disease course and immunosuppressive therapy increase the risk for emerging malignancies compared to those who have a normal colon [22-24]. …”

Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository

“…Oral 5-ASA treatment is also important for inhibiting extension of ulcerative proctitis [7]. Long-term cases of ulcerative colitis even in proctitis type may be in risks of cancer [12]. …”